Overview

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection with Mycobacterium tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents
Phase:
Phase 2
Details
Lead Sponsor:
Aeras
Collaborator:
Sanofi Pasteur, a Sanofi Company
Treatments:
BCG Vaccine